Pure Global

Clinical Trial - Trial KCT0007091

Access comprehensive clinical trial information for KCT0007091 through Pure Global AI's free database. This Phase 2 trial is sponsored by Yonsei University Health System, Severance Hospital and is currently Recruiting. The study focuses on Non-small cell lung cancer.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Korean Clinical Trial Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
KCT0007091
Phase 2
Recruiting
Trial Details
Korean Clinical Trial Registry โ€ข KCT0007091
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Untitled Trial
Open-label Phase II Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer(GENUINE)

Study Focus

Interventional

Sponsor & Location

Yonsei University Health System, Severance Hospital

Genexine

South Korea

Timeline & Enrollment

Phase 2

N/A

N/A

ICD-10 Classifications

Secondary malignant neoplasm of lung
Malignant neoplasm: Lower lobe, bronchus or lung
Malignant neoplasm: Middle lobe, bronchus or lung
Malignant neoplasm: Bronchus or lung, unspecified
Malignant neoplasm of bronchus and lung

Data Source

Korean Clinical Trial Registry

KCT0007091

Non-Device Trial